



# Bridging the consumer-clinic revenue gap to the \$42 billion mHealth market

Arnold Bos

Consultant – EMEA region


June 16<sup>th</sup>, 2015



**lux**executivesummit

Amsterdam • June 15-16, 2015

# mHealth technology is a key enabler of the shift to decentralized healthcare



# Opportunities for mHealth are almost anywhere

Emergency  
medicine



Sport &  
Fitness



In-field / remote  
settings



Food &  
Nutrition



Primary  
care



Self  
management



Home  
Care



Chronic  
care




Security &  
Safety



Clinical markets


Consumer markets

# By 2023, mHealth will grow over \$41 billion; vital sign monitoring will remain one of the cornerstones




- Clarification of regulatory approaches will help the clinical space grow
- Decision-support algorithms will actively drive adoption of mHealth devices
- Vital signs monitoring (VS) and IVD are the cornerstones of the mHealth industry and will make up 80% of the mHealth devices market by 2023



# Technologies that can transition the consumer-clinical gap, can capitalize in both markets



# Leveraging the analytics is critical to generate revenue




# Emerging devices can measure more relevant biomarkers, with increasing accuracy




Bacteria Name	You	Average
Firmicutes	50.0%	61.1%
Bacteroidetes	26.5%	21.0%
Proteobacteria	9.92%	3.12%
Actinobacteria	4.49%	2.66%
Cyanobacteria	3.32%	0.180%

# mHealth needs analytics to help translate big data into actionable recommendations





# To get to the big money, companies must build their path to the clinical market



- After a slow start, developing markets leap-frogging technology adoption, combined with clarification of regulations, will see the clinical market expand rapidly
- In 2023, clinical applications constitute a market value of \$16 billion and represents 70% of the total mHealth vital signs monitoring market.

# mHealth startups utilize different strategies to bridge the revenue gap



- Targeting consumer applications, compatible with **third-party apps**
- Technology platform designed with **potential for clinical accuracy**



- Wearable + ingestible device is **unfamiliar territory for FDA approval**
- **Targets the consumer market** with sensor product only



- Wearable **accuracy on par with current clinical** monitoring equipment
- **Software can analyze and evaluate** patient data to alert patient and caregivers



- **Open-access analysis platform**, aimed to find causes for the gathered data
- Developed optical sensor, to **incorporate into third-parties'** wearables

# Can the technology transition the consumer-clinical revenue gap?



- Can the technology provide **meaningful, actionable information** for consumers?
- Will the product generate revenue to **fund further technology development**?
- Can the technology **claim the accuracy needed** for the regulated clinical market?
- Can my sensor package be **downsized for consumer applications**?

➤ Can the technology evolve to enter the clinical market in the long-term?

➤ Can the technology capture consumer applications for short-term revenue?



# Thank you



**luxresearch**

Arnold Bos  
Consultant

[Arnold.bos@luxresearchinc.com](mailto:Arnold.bos@luxresearchinc.com)

+31 20 808 7536